Nobel Prize winner Demis Hassabis thinks human trials will happen soon Clinical trials of the first drugs designed with the ...

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...

This article originally appeared on Nashville Tennessean: Vanderbilt graduate John Jumper wins Nobel Prize in chemistry for ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trials of drugs designed using AI to start late this year.

John Jumper, a Nobel laureate and a central figure in computational biology, presented a groundbreaking PhD thesis titled "New Methods Using Rigorous .

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year.

He tells Sumiko Tan how he spent long summers in Singapore as a child with his Singapore-born mum. Read more at ...

Hassabis, 48, CEO and co-founder of Google DeepMind, developed the AI model AlphaFold to predict protein structure with company co-founder John Jumper. Proteins are made up of amino acids linked ...

The project was led by Google DeepMind CEO Demis Hassabis and Director John Jumper. Drug development is ... has traditionally been made. But now, AI systems are poised to dramatically accelerate ...

Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this ...

have provided crucial mathematical and algorithmic underpinnings for AI models. Besides, Nobel Prize winners for Chemistry Demis Hassabis and John Jumper have demonstrated the immense potential of ...